Payment overview · 2025
General Payments
$399.72
17 reported records · 6 companies
Healthcare provider profile · identity verified
Anthony Bae, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · YORBA LINDA, CA · NPI 1194711945
Verified facts
What the public records show
CMS Open Payments records show Anthony Bae, M.D. received $399.72 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Mounjaro, Ozempic, Rybelsus, Wegovy.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.95 | 24.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.57 | 22.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $84.00 | 21.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.66 | 16.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.57 | 10.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.97 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.72 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $84.00 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.49 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.49 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $66.66 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1267 | 350 |
| Amlodipine Besylate | Amlodipine Besylate | 614 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 577 | 151 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 524 | 156 |
| Simvastatin | Simvastatin | 378 | 104 |
| Losartan Potassium | Losartan Potassium | 301 | 91 |
| Lisinopril | Lisinopril | 277 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 88 |
| Alendronate Sodium | Alendronate Sodium | 242 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 71 |
| Metformin Hcl | Metformin Hcl | 219 | 65 |
| Eliquis | Apixaban | 197 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 52 |
| Gabapentin | Gabapentin | 179 | 55 |
| Omeprazole | Omeprazole | 177 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 60 |
| Metformin Hcl Er | Metformin Hcl | 148 | 49 |
| Potassium Chloride | Potassium Chloride | 146 | 46 |
| Furosemide | Furosemide | 139 | 52 |
| Allopurinol | Allopurinol | 136 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 61 |
| Atenolol | Atenolol | 126 | 33 |
| Ozempic | Semaglutide | 126 | 29 |
| Finasteride | Finasteride | 124 | 37 |
| Celecoxib | Celecoxib | 118 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 31 |
| Tramadol Hcl | Tramadol Hcl | 106 | 21 |
| Montelukast Sodium | Montelukast Sodium | 105 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 28 |
| Jardiance | Empagliflozin | 97 | 28 |
| Valsartan | Valsartan | 96 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 32 |
| Ezetimibe | Ezetimibe | 94 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 32 |
| Synthroid | Levothyroxine Sodium | 91 | 26 |
| Sertraline Hcl | Sertraline Hcl | 90 | 26 |
| Benazepril Hcl | Benazepril Hcl | 86 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 25 |
| Spironolactone | Spironolactone | 86 | 25 |
| Alprazolam | Alprazolam | 85 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 22 |
| Terazosin Hcl | Terazosin Hcl | 81 | 23 |
| Famotidine | Famotidine | 80 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 26 |
| Carvedilol | Carvedilol | 76 | 22 |
| Bupropion Xl | Bupropion Hcl | 74 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Mirtazapine | Mirtazapine | 70 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 22 |
| Irbesartan | Irbesartan | 66 | 19 |
| Clonazepam | Clonazepam | 64 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 33 |
| Lovastatin | Lovastatin | 61 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 59 | 18 |
| Lorazepam | Lorazepam | 59 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 15 |
| Prednisone | Prednisone | 55 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 15 |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Nifedipine Er | Nifedipine | 49 | 12 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 47 | 12 |
| Donepezil Hcl | Donepezil Hcl | 46 | 15 |
| Telmisartan | Telmisartan | 46 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 28 |
| Januvia | Sitagliptin Phosphate | 43 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 13 |
| Klor-Con 10 | Potassium Chloride | 42 | 15 |
| Xarelto | Rivaroxaban | 42 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 15 |
| Warfarin Sodium | Warfarin Sodium | 41 | 13 |
| Lactulose | Lactulose | 40 | suppressed |
| Meloxicam | Meloxicam | 38 | 16 |
| Trazodone Hcl | Trazodone Hcl | 38 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 23 |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 29 |
| Nystatin | Nystatin | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | 11 |
| Ketoconazole | Ketoconazole | 33 | 17 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 32 | 23 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Wegovy | Semaglutide | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Felodipine Er | Felodipine | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diovan | Valsartan | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | 11 |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Pulmicort Flexhaler | Budesonide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.72 · 17 records | Amgen Inc. | AREXVY, ELIQUIS, FREESTYLE LIBRE 3, KRYSTEXXA, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error